Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 avr. 2024 07h30 HE | Source: Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
21 mars 2024 07h30 HE | Source: Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

MARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
06 mars 2024 10h30 HE | Source: Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
31 janv. 2024 08h00 HE | Source: Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
07 déc. 2023 08h00 HE | Source: Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...